Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 2, 2006, Pages 179-183

  Pace, Leonardo ^a,b   Klain, Michele ^a   Albanese, Carmine ^a   Salvatore, Barbara ^a   Storto, Giovanni ^b   Soricelli, Andrea ^c   Salvatore, Marco ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c Università Degli Studi Parthenope   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PAPILLARY CARCINOMA; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS; THYROXINE; TREATMENT OUTCOME;

EID: 31444438522     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1929-2     Document Type: Article

References (33)

1. Ozata M, Suzuki S, Myamoto T, Liu RT, Fierro-Renoy F, Degrot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105
2. Duren M, Siperstein AE, Sheen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high and low-risk patients. Surgery 1999;126:13-9
3. Pacini F, Pinchera A. Serum and tissue thyroglobulin measurements: clinical applications in thyroid disease. Biochimie 1999;81:463-7
4. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41
5. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Tadei D, Pinchera A. Diagnostic 131-1 whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501
6. Lind P. I-131 whole body scintigraphy in thyroid cancer patients. Q J Nucl Med 1999;43:188-94
7. Lind P. Should high hTg levels in the absence of iodine uptake be treated? For. Eur J Nucl Med Mol Imaging 2003;30:157-60
8. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-7
9. Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancer. J Nucl Med 1979;20:92-7
10. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 1985;23:405-11
11. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-ray. J Nucl Med 1988;29:1790-4
12. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-34
13. Reynolds JC. Percent 131-I uptake and post-therapy 131-I scans: their role in the management of thyroid cancer. Thyroid 1997;7:281-4
14. Schlumberger M. Use of radioactive iodine in patients with papillary and follicular thyroid cancer: toward a selective approach. J Clin Endocrinol Metab 1988;83:4201-3
15. Bierman M, Schober O. Should high hTg levels in the absence of iodine uptake be treated? Against. Eur J Nucl Med Mol Imaging 2003;30:160-3
16. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: comparison of patients treated with high 131-I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7
17. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tg positive, diagnostic whole body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002;87:1521-6
18. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-92
19. Koh JM, Kim Es, Ryu JS, Hong SJ, Kim WB, Shong YK. Effects of therapeutic doses of 131-I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131-I whole body scan: comparative study. Clin Endocrinol 2003;58:421-7
20. Venkataraman GM, Yatin M, Ain KB. Cloning of the human sodium-iodine symporter promoter and characterization in a different human thyroid cell line. Thyroid 1998;8:63-9
21. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, et al. Expression of the Na+7I - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228-34
22. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998;83:2493-6
23. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131-I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639-45
24. Robbins RJ, Schlumberger MJ. The evolving role of 131-I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005;46:28S-37S
25. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids: a review. Exp Clin Endocrinol Diabetes 2001;109:41-4
26. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002;20:S492-6
27. Stokkel MPM, Verkooijen RB, Smit JWA. Indium-111 octreotide scintigraphy for the detection of non-functioning metastasis from differentiated thyroid cancer: diagnostic and prognostic value. Eur J Nucl Med Mol Imaging 2004;31:950-7
28. 131I whole-body scans. Eur J Nucl Med Mol Imaging 2004;31:330-41
29. 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:3779-86
30. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131-I scan. J Nucl Med 2001;42:71-6
31. Helal BO, Merlot P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, et al. Clinical impact of 18-F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131-I scanning results after therapy. J Nucl Med 2001;42:1464-9
32. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131-I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010-5
33. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of (18F)fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-13